Neurocrine Biosciences (NASDAQ:NBIX) Upgraded to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Neurocrine Biosciences (NASDAQ:NBIXFree Report) from a buy rating to a strong-buy rating in a research report report published on Monday.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright increased their price target on Neurocrine Biosciences from $150.00 to $160.00 and gave the company a buy rating in a research note on Thursday, May 2nd. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a buy rating in a research note on Thursday, May 2nd. Oppenheimer upped their price target on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an outperform rating in a research note on Thursday, May 2nd. Evercore ISI initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, May 14th. They issued an outperform rating and a $175.00 price target on the stock. Finally, BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a market perform rating in a report on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $150.85.

View Our Latest Research Report on NBIX

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $139.92 on Monday. The stock has a market cap of $14.08 billion, a P/E ratio of 38.55 and a beta of 0.36. The company has a fifty day moving average price of $138.26 and a two-hundred day moving average price of $133.26. Neurocrine Biosciences has a one year low of $91.29 and a one year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The business had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 4.19 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Ingrid Delaet sold 1,800 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.03, for a total transaction of $252,054.00. Following the sale, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,051,205.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock in a transaction on Friday, March 8th. The stock was sold at an average price of $140.03, for a total transaction of $252,054.00. Following the transaction, the insider now owns 7,507 shares in the company, valued at approximately $1,051,205.21. The disclosure for this sale can be found here. Insiders sold a total of 212,497 shares of company stock worth $29,263,354 in the last three months. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. RFP Financial Group LLC raised its holdings in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Mather Group LLC. bought a new position in Neurocrine Biosciences during the first quarter worth $26,000. Lindbrook Capital LLC lifted its holdings in Neurocrine Biosciences by 85.0% in the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares during the period. EdgeRock Capital LLC bought a new stake in Neurocrine Biosciences during the fourth quarter valued at $31,000. Finally, New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences during the first quarter valued at $32,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Read More

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.